Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Glenmark Therapeutics Inc., USA launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals has received final approval from the US FDA for its Fluticasone Propionate Nasal Spray USP, 50 mcg per spray, an over-the-counter (OTC) product. The spray is bioequivalent to Haleon's Flonase Allergy Relief Nasal Spray and will be distributed in the US by Glenmark's subsidiary, Glenmark Therapeutics Inc. This is the first OTC nasal spray Glenmark will sell in the US through this subsidiary, with launch planned for April 2026. The reference Flonase market in the US generated annual sales of approximately $384.7 million based on Nielsen data for the 52 weeks ending March 3, 2026.
Positive for shareholders — opens a new OTC revenue stream in the large US allergy nasal spray market (~$385 million annually), strengthening Glenmark's US generics and consumer health presence. Short-term stock impact may be modest as the company will compete against an established brand, but it adds a meaningful growth lever.